Literature DB >> 27050476

Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis.

Christy Lai Ming Hui1, Venessa Wing Yan Poon2, Wai Tung Ko2, Ho Yee Miao2, Wing Chung Chang3, Edwin Ho Ming Lee2, Sherry Kit Wa Chan3, Jingxia Lin2, Eric Yu Hai Chen3.   

Abstract

BACKGROUND: Research on antipsychotic medication non-adherence in first-episode psychosis patients tends to examine non-adherence behaviors and attitudes together. Nonetheless, attitudes do not always directly translate into behaviors. We examined the baseline predictors for antipsychotics non-adherence behaviors and attitudes separately in a first-episode psychosis cohort. We also included cognitive impairments as one of the predictor variables as this domain is rarely explored in adherence studies.
METHOD: Participants were 313 adult-onset psychosis patients recruited from the Jockey Club Early Psychosis project in Hong Kong. Demographic, premorbid, clinical, and cognitive characteristics were first assessed at baseline. Six months later, participants completed a 14-item Medication Compliance Questionnaire, which was a modified and Cantonese-translated version of the Medication Adherence Rating Scale that includes items pertaining to both adherence behaviors and attitudes.
RESULTS: Rates of poor adherence behaviors and negative adherence attitudes were 17.6% and 27.8%, respectively. Determinants of poor adherence behavior included more severe positive symptoms, hospitalization at onset of illness, and poorer engagement in extended social network. As for negative adherence attitude, determinants included more severe general psychopathology, poorer insight, more psychic medication side-effects, and poorer performance on backward digit span test and WAIS-R information test.
CONCLUSIONS: The risk factors for non-adherence behaviors and attitudes are different and they should all be taken into careful consideration while formulating appropriate intervention programs to tackle the adherence problem in adult onset psychosis.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence; Antipsychotics; First-episode; Predictors; Psychosis

Mesh:

Substances:

Year:  2016        PMID: 27050476     DOI: 10.1016/j.schres.2016.03.026

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

1.  Defining disengagement from mental health services for individuals experiencing first episode psychosis: a systematic review.

Authors:  Siobhan Reynolds; Da Jung Kim; Ellie Brown; Rachel Tindall; Brian O'Donoghue
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-07-18       Impact factor: 4.328

2.  Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience.

Authors:  A Tinland; K Zemmour; P Auquier; M Boucekine; V Girard; S Loubière; G Fond; Laurent Boyer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-06-27       Impact factor: 4.328

3.  What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication.

Authors:  T Wykes; J Evans; C Paton; T R E Barnes; D Taylor; R Bentall; B Dalton; T Ruffell; D Rose; S Vitoratou
Journal:  Psychol Med       Date:  2017-04-19       Impact factor: 7.723

Review 4.  Antipsychotic-Related Stigma and the Impact on Treatment Choices: A Systematic Review and Framework Synthesis.

Authors:  Michael Townsend; Kristin Pareja; Amy Buchanan-Hughes; Emma Worthington; David Pritchett; Malaak Brubaker; Christy Houle; Tenna Natascha Mose; Heidi Waters
Journal:  Patient Prefer Adherence       Date:  2022-02-16       Impact factor: 2.711

5.  Dynamics between insight and medication adherence in first-episode psychosis: Study of 3-year trajectories.

Authors:  Julien Elowe; Julie Ramain; Alessandra Solida; Philippe Conus; Philippe Golay
Journal:  Eur Psychiatry       Date:  2022-08-15       Impact factor: 7.156

6.  Effectiveness of More Personalized, Case-Managed, and Multicomponent Treatment for Patients with Severe Schizophrenia Compared to the Standard Treatment: A Ten-Year Follow-Up.

Authors:  Juan J Fernández-Miranda; Silvia Díaz-Fernández; Francisco López-Muñoz
Journal:  J Pers Med       Date:  2022-07-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.